Epigenetic inhibitors

Methods in Molecular Biology

Volumn 1238, Issue , 2015, Pages 469-485

  Verma, Mukesh ^a   Banerjee, Hirendra Nath ^a  

^a NONE

Author keywords

Cancer; Chromatin; Epigenetics; Histone deacetylase; Histone inhibitors; Methylation; Methyltransferase; MicroRNAs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; ENZYME INHIBITOR; EPIGENETIC INHIBITOR; EPIGENETIC READER DOMAIN INHIBITOR; HISTONE DEACETYLASE INHIBITOR; METHYLATION INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER GROWTH; CANCER THERAPY; DNA METHYLATION; EPIGENETICS; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HISTONE ACETYLATION; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS;

EID: 84955355411     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-1804-1_24     Document Type: Article

References (196)

1. Sims RJ 3rd, Reinberg D (2004) From chromatin to cancer: a new histone lysine methyltransferase enters the mix. Nat Cell Biol 6: 685–687
2. Cavalli G (2006) Chromatin and epigenetics in development: blending cellular memory with cell fate plasticity. Development 133: 2089–2094
3. Brown MA, Sim RJ 3rd, Gottlieb PD et al (2006) Identification and characterization of Smyd2: a split SET/MYND domain- containing histone H3 lysine 36-specifi c methyltransferase that interacts with the Sin3 histone ceacetylase complex. Mol Cancer 5:26–28
4. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293:1074–1080
5. Jenuwein T (2006) The epigenetic magic of histone lysine methylation. FEBS J 273: 3121–3135
6. Festernstein R, Aragon L (2003) Decoding the epigenetic effects of chromatin. Genome Biol 4:342–345
7. Mito Y, Henikoff JG, Henikoff S (2005) Genome-scale profiling of histone H3.3 replacement patterns. Nat Genet 37:1090–1097
8. Barkess G (2006) Chromatin remodeling and genome stability. Genome Biol 7:319–322
9. Lewin B (2004) Genes VIII. Pearson Prentice Hall, Upper Saddle River, NJ
10. Wolffe AP, Matzke MA (1999) Epigenetics: regulation through repression. Science 286: 481–486
11. Issa JP, Baylin SB (1996) Epigenetics and human disease. Nat Med 2:281–282
12. Egger G, Liang G, Aparicio A et al (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463
13. Watson RE, Goodman JI (2002) Epigenetics and DNA methylation come of age in toxicology. Toxicol Sci 67:11–16
14. Staub E, Grone J, Mennerich D et al (2006) A genome-wide map of aberrantly expressed chromosomal islands in colorectal cancer. Mol Cancer 5:37–39
15. Baylin SB, Ohm JE (2006) Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6:107–116
16. Turner BM (2002) Cellular memory and the histone code. Cell 111:285–291
17. Richmond TJ (2006) Genomics: predictable packaging. Nature 442:750–752
18. Kornberg RD, Lorch Y (1999) Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. Cell 98: 285–294
19. Luger K, Mader AW, Richmond RK et al (1997) Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389:251–260
20. Yap KL, Zhou MM (2006) Structure and function of protein modules in chromatin biology. Results Probl Cell Differ 41:1–23
21. Khorasanizadeh S (2004) The nucleosome: from genomic organization to genomic regulation. Cell 116:259–272
22. Hayes JJ, Clark DJ, Wolffe AP (1991) Histone contributions to the structure of DNA in the nucleosome. Proc Natl Acad Sci U S A 88: 6829–6833
23. Vitolo JM, Thiriet C, Hayes JJ (2000) The H3-H4 N-terminal tail domains are the primary mediators of transcription factor IIIA access to 5S DNA within a nucleosome. Mol Cell Biol 20:2167–2175
24. Oudet P, Gross-Bellard M, Chambon P (1975) Electron microscope and biochemical evidence that chromatin structure is a repeating unit. Cell 4:281–300
25. Schalch T, Duda S, Sargent DF et al (2005) X-ray structure of a tetranucleosome and its implications for the chromatin fibre. Nature 4:281–300
26. Bharath MM, Chandra NR, Rao MR (2003) Molecular modeling of the chromatosome particle. Nucleic Acids Res 31:4264–4274
27. Bednar J, Horowitz RA, Grigoryev SA et al (1998) Nucleosomes, linker DNA, and linker histone form a unique structural motif that directs the higher-order folding and compaction of chromatin. Proc Natl Acad Sci U S A 95:14173–14178
28. Cui Y, Bustamante C (2000) Pulling a single chromatin fi ber reveals the forces that maintain its high-order structure. Proc Natl Acad Sci U S A 97:127–132
29. Robinson PJ, Rhodes D (2006) Structure of the ‘30 nm’ chromatin fibre: a key role for the linker histone. Curr Opin Struct Biol 16:336–343
30. Davey CA, Sargent DF, Luger K et al (2002) Solvent mediated interactions in the structure of the nucleosome core particle at 1.9 Å resolution. J Mol Biol 319:1097–1113
31. Vicent GP, Nacht AS, Smith CL et al (2004) DNA instructed displacement of histones H2A and H2B at an inducible promoter. Mol Cell 16:439–452
32. Adkins NL, Watts M, Gerogel PT (2004) To the 30-nm chromatin fiber and beyond. Biochim Biophys Acta 167:12–23
33. McBryant SJ, Adams VH, Hansen JC (2006) Chromatin architectural proteins. Chromosome Res 14:39–51
34. Reiner SL (2005) Epigenetic control in the immune response. Hum Mol Genet 14:41–46
35. Margueron R, Trojer P, Reinberg D (2005) The key to development: interpreting the histone code? Curr Opin Genet Dev 15: 163–176
36. Lin W, Dent SY (2006) Functions of histonemodifying enzymes in development. Curr Opin Genet Dev 16:137–142
37. Dannenberg JH, David G, Zhong S, et al (2005) mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes Dev 19:1581–1595
38. Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343–2360
39. Lachner M, Jenuwein T (2002) The many faces of histone lysine methylation. Curr Opin Cell Biol 14:286–298
40. Kouzarides T (2002) Histone methylation in transcriptional control. Curr Opin Genet Dev 14:198–209
41. Bernstein E, Hake SB (2006) The nucleosome: a little variation goes a long way. Biochem Cell Biol 84:505–517
42. Lund AH, van Lohuizen M (2004) Epigenetics and cancer. Genes Dev 18:2315–2335
43. Fraga MF, Esteller M (2005) Towards the human cancer epigenome: a first draft of histone modifications. Cell Cycle 4:1377–1381
44. Agrelo R, Cheng WH, Setien F et al (2006) Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proc Natl Acad Sci U S A 103:8822–8827
45. Dhillon N, Kamakaka RT (2002) Breaking through to the other side: silencers and barriers. Curr Opin Genet Dev 12:188–192
46. Thomas MC, Chiang CM (2006) The general transcription machinery and general cofactors. Crit Rev Biochem Mol Biol 41: 105–178
47. Wittenberg C, Reed SI (2005) Cell cycledependent transcription in yeast: promoters, transcription factors, and transcriptomes. Oncogene 24:2746–2755
48. Ney PA (2006) Gene expression during terminal erythroid differentiation. Curr Opin Hematol 13:203–208
49. Teng CT (2006) Factors regulating lactoferrin gene expression. Biochem Cell Biol 84:263–267
50. Olson EN (2006) Gene regulatory networks in the evolution and development of the heart. Science 313:1922–1927
51. Johnson CN, Adkins NL, Georgel P (2005) Chromatin remodeling complexes: ATPdependent machines in action. Biochem Cell Biol 83:405–417
52. Becker PB, Hörz W (2002) ATP-dependent nucleosome remodeling. Annu Rev Biochem 71:247–273
53. Horn PJ, Peterson CL (2001) The bromodomain: a regulator of ATP-dependent chromatin remodeling? Front Biosci 6:D1019–D1023
54. Chen T, Li E (2006) Establishment and maintenance of DNA methylation patterns in mammals. Curr Top Microbiol Immunol 301:179–201
55. Herman JG, Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042–2054
56. Pradhan S, Esteve PO (2003) Mammalian DNA (cytosine-5) methyltransferase and their expression. Clin Immunol 109:6–16
57. Laird PW, Jaenisch R (1996) The role of DNA methylation in cancer genetics and epigenetics. Annu Rev Genet 30:441–464
58. Jones PA (2002) DNA methylation and cancer. Oncogene 21:5358–5360
59. Cross SH, Bird AP (1995) CpG islands and genes. Curr Opin Genet Dev 5:309–314
60. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261–282
61. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971–3993
62. Graff JR, Herman JG, Myohanen S (1997) Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 272:22322–22329
63. Bestor TH (1998) The host defence function of genomic methylation patterns. Novartis Found Symp 214:187–195, discussion 195–199, 228–232
64. Baylin SB, Herman JG, Graff JR et al (1998) Alterations in DNA methlyation: a fundamental aspect of neoplasia. Adv Cancer Res 72:141–196
65. Barlow DP (1995) Genetic imprinting in mammals. Science 270:1610–1613
66. Goto T, Monk M (1998) Regulation of X-chromosome inactivation in development in mice and humans. Microbiol Mol Biol Rev 62:362–378
67. Bird AP, Wolffe AP (1999) Methylationinduced repression–belts, braces, and chromatin. Cell 99:451–454
68. Jones PL, Veenstra GJ, Wade PA et al (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 19:187–191
69. Jones PL, Wolffe AP (1999) Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol 9:339–347
70. Jaenisch R, Bird A (2003) Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 33(Suppl):245–254
71. Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429–2440
72. Dutnall RN, Denu JM (2002) Methyl magic and HAT tricks. Nat Struct Biol 9:888–891
73. McManus KJ, Hendzel MJ (2006) The relationship between histone H3 phosphorylation and acetylation throughout the mammalian cell cycle. Biochem Cell Biol 84: 640–657
74. Daujat S, Bauer UM, Shav V et al (2002) Crosstalk between CARM1 methylation and CBP acetylation on histone H 3. Curr Biol 12:2090–2097
75. Dillon N, Festenstein R (2002) Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet 18:252–258
76. Verdone L, Caserta M, Di Mauro E (2005) Role of histone acetylation in the control of gene expression. Biochem Cell Biol 83: 344–353
77. Verdone L, Agricola E, Caserta M et al (2006) Histone acetylation in gene regulation. Brief Funct Genomic Proteomic 5:209–221
78. Umlauf D, Goto Y, Feil R (2004) Site-specific analysis of histone methylation and acetylation. Methods Mol Biol 287:99–120
79. de Ruijter AJ, van Gennip AH, Caron HN et al (2003) Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 370:737–749
80. Agalioti T, Chen G, Thanos D (2002) Deciphering the transcriptional histone acetylation code for a human gene. Cell 111:381–392
81. Brownell JE, Zhou J, Ranalli T et al (1996) Tetrahymena histone acetyltransferase A: ahomolog to yeast Gen5p linking histone acetylation to gene activation. Cell 84:843–851
82. Kimura A, Matsubara K, Horikoshi M (2005) A decade of histone acetylation: marking eukaryotic chromosomes with specific codes. J Biochem 138:647–662
83. Yang XJ (2004) The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32:959–976
84. Gregoretti IV, Lee YM, Goodson HV (2004) Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338:17–31
85. Tsukada Y, Fang J, Erdjument-Bromage H et al (2006) Histone demethylation by a family of JmjC domain-containing proteins. Nature 439:811–816
86. Wang H, An W, Cao R et al (2003) Mam facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol Cell 12: 475–487
87. Santos-Rosa H, Schneider R, Bannister AJ et al (2002) Active genes are tri-methylated at K4 of histone H 3. Nature 419:407–411
88. Shi Y, Lan F, Matson C et al (2004) Histone demethylation mediated by the nuclear amine oxidase homolog LSD 1. Cell 119:941–953
89. Mattick JS, Makunin IV (2006) Non-coding RNA. Hum Mol Genet 15:17–29
90. Kavi HH, Fernandez HR, Xie W et al (2005) RNA silencing in Drosophila. FEBS Lett 579:5940–5949
91. Kawasaki H, Taira K (2004) Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 431:211–217
92. Morris KV, Chan SW, Jacobsen SE et al (2004) Small interfering RNA-induced transcriptional gene silencing in human cells. Science 305:1289–1292
93. Singh U, Fohn LE, Wakayama T et al (2004) Different molecular mechanisms underlie placental overgrowth phenotypes caused by interspecies hybridization, cloning, and Esx1 mutation. Dev Dyn 230:149–164
94. Bernstein E, Allis CD (2005) RNA meets chromatin. Genes Dev 19:1635–1655
95. Saito Y, Liang G, Egger G et al (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin- modifying drugs in human cancer cells. Cancer Cell 9:435–443
96. Kinzler KW, Vogelstein B (1997) Cancersusceptibility genes Gatekeepers and caretakers. Nature 386:761–763
97. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1:157–162
98. Galm O, Herman JG, Baylin SB (2006) The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 20:1–13
99. Esteller M, Fraga MF, Guo M et al (2001) DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 10:30001–30007
100. Grady WM, Willis J, Guilford PJ et al (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16–17
101. Jones PA, Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415–428
102. Herman JG, Baylin SB (2000) Promoterregion hypermethylation and gene silencing in human cancer. Curr Top Microbiol Immunol 249:35–54
103. Merlo A, Herman JG, Mao L et al (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1:686–692
104. Leone G, Teofili L, Voso MT et al (2002) DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Hematologica 87:1324–1341
105. Herman JG (1999) Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol 9:359–367
106. Herman JG, Latif F, Weng Y et al (1994) Silencing of the WHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A 91:9700–9704
107. Feinberg AP, Tycko B (2004) The history of cancer epigenetics. Nat Rev Cancer 4:143–153
108. Burzynski SR (2003) Gene silencing–a new theory of aging. Med Hypotheses 60: 578–583
109. Herman JG, Civin CI, Issa JP et al (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837–841
110. Uchida T, Kinoshit T, Nagai H et al (1997) Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90: 1403–1409
111. Quesnel B, Guillerm G, Vereecque R et al (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990
112. Galm O, Wilop S, Luders C et al (2005) Clinical implications of aberrant DNAmethylation patterns in acute myelogenous leukemia. Ann Hematol 84(Suppl 13): 39–46
113. Melki JR, Vincent PC, Clark SJ (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59:3730–3740
114. Toyota M, Kopecky KJ, Toyota MO et al (2001) Methylation profiling in acute myeloid leukemia. Blood 97:2823–2829
115. Shiozawa E, Takimoto M, Makino R et al (2006) Hypermethylation of CpG islands in p16 as a prognostic factor for diffuse large B-cell lymphoma in a high-risk group. Leuk Res 30:859–867
116. Guillerm G, Gyan E, Wolowiec D et al (2001) p16(INK4a) and p15(INK4b) gene methylations in plasma cells from monoclonal gammopathy of undetermined significance. Blood 98:244–246
117. Mateos MV, Garcia-Sanz R, Lopez-Perez R et al (2001) p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J 2:146–149
118. Uchida T, Kinoshita T, Ohno T et al (2001) Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia. Leukemia 15:157–165
119. Khan S, Kumagai T, Vora J et al (2004) PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 112:407–410
120. Garcia JM, J Silva C, Pena V et al (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41:117–124
121. Dominguez G, Silva J, Garcia JM et al (2003) Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors. Mutat Res 530:9–17
122. Kang YH, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82:285–291
123. Tang S, Luo H, Yu J et al (2003) Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis. Chin Med J (Engl) 116:1083–1087
124. Pu RT, Laitala LE, Alli PM et al (2003) Methylation profi ling of benign and malignant breast lesions and its application to cytopathology. Mod Pathol 16:1095–1101
125. Padar A, Sathyanaraynana UG, Suzuki M et al (2003) Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. Clin Cancer Res 9:4730–4734
126. Wong NA, Britton MP, Choi GS et al (2004) Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. Proc Natl Acad Sci U S A 101:574–579
127. Li Q, Ahuja N, Burder PC et al (1999) Methylation and silencing of the Thrombo spondin-1 promoter in human cancer. Oncogene 18:3284–3289
128. Whitcomb BP, Mutch DG, Herzog TJ et al (2003) Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin Cancer Res 9:2277–2287
129. Cameron EE, Bachman KE, Myohanen S et al (1999) Synergy of demethylation and histone deacetylase inhibition in the reexpression of genes silenced in cancer. Nat Genet 21:103–107
130. Lou W, Krill D, Dhir R et al (1999) Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 59:2329–2331
131. Kudo Y, Kitajima S, Ogawa I et al (2004) Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous beta-catenin. Clin Cancer Res 10:5455–5463
132. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41–45
133. Kornblitz AB, Herndon JE 2nd, Silverman LR et al (2002) Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20:2441–5242
134. Kaminskas E, Farrel A, Abraham S, FDA et al (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604–3608
135. Kantarjian H, Issa JP, Rosenfeld CS et al (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794–1803
136. Momparler RL (2013) Epigenetic therapy of non-small cell lung cancer using decitabine (5-aza-2'-deoxycytide). Front Oncol 3: 188–192
137. Batova A, Diccianni MB, Yu JC et al (1997) Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57:832–836
138. Aoki E, Uchida T, Ohashi H et al (2000) Methylation status of the p15INK4B gene in hematopoietic progenitors and peripheral blood cells in myelodysplastic syndromes. Leukemia 14:586–593
139. Daskalakis M, Nguyen TT, Nguyen C et al (2002) Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2’-deoxycytidine (decitabine) treatment. Blood 100:2957–2964
140. Scott SA, Dong WF, Ichinohasama R et al (2006) 5-Aza-2’-deoxycitidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk Res 30:69–76
141. Kumagai T, Wakimoto N, Yin D et al (2007) Histone deacetylase inhibitor, Suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer 121:656–665
142. Marks P, Rifkind RA, Richon VM et al (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202
143. Lavau C, Du C, Thirman M et al (2000) Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J 19:4655–4664
144. Kalebic T (2003) Epigenetic changes: potential therapeutic targets. Ann N Y Acad Sci 983:278–285
145. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210–1216
146. Hiebert SW, Lutterbach B, Amann J (2001) Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins. Curr Opin Hematol 8:197–200
147. Di Croce L, Raker VA, Corsaro M et al (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079–1782
148. Carbone R, Botugno OA, Ronzoni S et al (2006) Recruitment of the histone methyltransferase SUV39H1 and its role in the oncogenic properties of the leukemiaassociated PML-retinoic acid receptor fusion protein. Mol Cell Biol 26:1288–1296
149. Liu S, Shen T, Huynh L et al (2005) Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 65:1277–1284
150. Jones PL, Wade PA, Wolffe AP (2001) Purifi cation of the MeCP2/histone deacetylase complex from Xenopus laevis. Methods Mol Biol 181:297–307
151. Fuks F, Hurd PJ, Wolf D et al (2003) The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035–4040
152. Kondo Y, Shen L, Issa JP (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 23:206–215
153. Rountree MR, Bachman KE, Herman JG et al (2001) DNA methylation, chromatin inheritance, and cancer. Oncogene 20: 3156–3165
154. Robertson KD, Ait-Si-Ali S, Yokochi T et al (2000) DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25:338–342
155. Bannister AJ, Kouzarides T (2004) Histone methylation: recognizing the methyl mark. Methods Enzymol 376:269–288
156. Nguyen CT, Weisenberger DJ, Velicescu M et al (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza- 2’-deoxycytidine. Cancer Res 62:6456–6461
157. Thiagalingam S, Cheng KH, Lee HJ et al (2003) Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 983:84–100
158. Momparler RL (2003) Cancer epigenetics. Oncogene 22:6479–6483
159. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287–299
160. Drummond DC, Noble CO, Kirpotin DB et al (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45:495–529
161. Mann BS, Johnson JR, Cohen MH et al (2007) FDA approval summary: varinostat for treatment of advanced primary cutaneous T cell lymphoma. Oncologist 12:1247–1252
162. Insinga A, Monestiroli S, Ronzoni S et al (2005) Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11:71–76
163. Warrener R, Beamish H, Burgess A et al (2003) Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J 17:1550–1552
164. Qiu L, Burgess A, Fairlie DP et al (2000) Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 11:2069–2083
165. Yin D, Ong JM, Desmond JC et al (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13:1045–1052
166. Luong QT, O’Kelly J, Braunstein GD et al (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570–5577
167. Komatsu N, Kawamata N, Takeuchi S et al (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 15:187–191
168. Sakajiri S, Kumagai T, Kawamata N et al (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33:53–61
169. Takai N, Kawamata N, Gui D et al (2004) Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101:2760–2770
170. Takai N, Desmond JC, Kumagai T et al (2004) Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10:1141–1149
171. Amin HM, Saeed S, Alkan S (2001) Histone deacetylase inhibitors induce caspase- dependent apoptosis and downregulation of daxx in acute promyelocytic leukemia with t(15;17). Br J Haematol 115:287–297
172. Munster PN, Troso-Sandoval T, Rosen N et al (2001) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 61:8492–8497
173. Marchoin DC, Bicaku E, Daud AI et al (2004) Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92:223–237
174. McCaffrey PG, Newsome DA, Fibach E et al (1997) Induction of gamma-globin by histone deacetylase inhibitors. Blood 90:2075–2083
175. Cao H, Stamatoyannopoulos S, Jung M (2004) Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 103:701–709
176. Blagosklonny MV, Robey R, Sackett DL et al (2002) Histone deacetylase inhibitors all induce p21 but differentially cause tubulin acetylation, mitotic arrest, and cytotoxicity. Mol Cancer Ther 1:937–941
177. Fang JY, Lu YY (2002) Effects of histone acetylation and DNA methylation on p21 (WAF1) regulation. World J Gastroenterol 8:400–405
178. Pace BS, White GL, Dover GJ et al (2002) Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood 100:4640–4648
179. Richon VM, Sandhoff TW, Rifkind RA et al (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and geneassociated histone acetylation. Proc Natl Acad Sci U S A 97:10014–10019
180. Sasakawa T, Naoe T, Inoue T et al (2002) Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol 64:1079–1090
181. Saito A, Tamashita T, Mariko Y et al (1999) A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A 96:4592–4597
182. Cang S, Lu Q, Ma Y et al (2010) Clinical advances in hypomethylating agents targeting epigenetic pathways. Curr Cancer Drug Targets 10:539–545
183. Camphausen K, Burgan W, Cerra M et al (2004) Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275. Cancer Res 64:316–321
184. Camphausen K, Cerna D, Scott T et al (2005) Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int J Cancer 114:380–386
185. Facchetti F, Previdi S, Ballarini M et al (2004) Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9:573–582
186. Fandy TE, Srivastava RK (2006) Trichostatin A sensitizes TRAIL-resistant myeloma cells by downregulation of the antiapoptotic Bcl-2 proteins. Cancer Chemother Pharmacol 58:471–477
187. Ganesan A, Nolan L, Crabb SJ et al (2009) Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 9:963–981
188. Goldsmith KC, Hogarty MD (2005) Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Lett 228:133–141
189. Kim SH, Ahn S, Han JW et al (2004) Apicidin is a histone deacetylase inhibitor with antiinvasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315:964–970
190. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600–608
191. Nome RV, Bratland A, Harman G et al (2005) Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiationinduced cell death. Mol Cancer Ther 4: 1231–1238
192. Paroni G, Mizzau M, Henderson C et al (2004) Caspase-dependent regulation of histone deacetylase 4 nuclear-cytoplasmic shuttling promotes apoptosis. Mol Biol Cell 15:2804–2818
193. Ree AH, Dueland S, Folkvord S et al (2010) Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol 11:459–464
194. Shanker S, Srivastava R (2008) Histone deacetylase inhibitors: mechanism and clinical signifi cance in cancer. Adv Exp Med Biol 615:261–298
195. Siegel D, Hussein M, Belani C et al (2009) Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2:31–37
196. Falchook GS, Fu S, Naing A et al (2013) Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs 31:1192–1200